INTRODUCTION: @entity3264 ( @entity7647 ) has been suggested to have a beneficial influence on outcomes of @entity3124 @entity1 . However, recent large-scale trials have suggested harm associated with @entity7647 supplementation. Recently, systematic reviews on the use of parenteral @entity7647 have been published; however, less information is available on the role of enteral @entity7647 . Therefore, the aim of this systematic review was to study the effects of enteral @entity7647 supplementation in @entity1 with @entity3124 . METHODS: We identified randomized controlled trials conducted from 1980 to 2014 with enterally administered @entity7647 in adult @entity3124 @entity1 . Studies of parenteral @entity7647 only or combined enteral-parenteral @entity7647 were excluded. The methodological quality of studies was scored, and trial data were statistically combined. We examined a priori the treatment effects in subgroups of trials of burn and @entity130 @entity1 . RESULTS: A total of 11 studies involving 1079 adult @entity3124 @entity1 and enteral @entity7647 supplementation were identified. Enteral @entity7647 supplementation was not associated with a reduction of hospital mortality (risk ratio [RR] 0.94, 95% confidence interval [CI] 0.65-1.36; p = 0.74), infectious complications (RR 0.93, 95% CI 0.79-1.10; p = 0.39) or stay in the intensive care unit ( @entity353 [ @entity353 ] -1.36 days, 95% CI -5.51 to 2.78; p = 0.52). However, there was a significant reduction in hospital stay ( @entity353 4.73 days, 95% CI -8.53 to -0.90; p = 0.02). In the subset of studies of @entity1 with burns, enteral @entity7647 supplementation was associated with significant reductions in hospital mortality (RR 0.19, 95% 0.06-0.67; p = 0.010) and hospital stay ( @entity353 -9.16, 95% CI -15.06 to -3.26; p = 0.002). There was no effect in @entity130 @entity1 . CONCLUSIONS: Enteral @entity7647 supplementation does not confer significant clinical benefit in @entity3124 @entity1 , with the exception of reduced hospital stay. There may be a significant benefit in @entity1 with burns, but data are sparse and larger randomized trials are warranted to confirm this effect.

Enteral XXXX supplementation in @entity3124 @entity1 : a systematic review and meta-analysis.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3264 :: ('D018698', 'Chemical') :: ['Glutamine'] @entity353 :: ('MESH:D015431', 'Disease') :: ['WMD', 'weighted mean difference'] @entity3124 :: ('MESH:D016638', 'Disease') :: ['critical illness', 'critically ill'] @entity7647 :: ('CHEBI:32668', 'Chemical') :: ['GLN'] @entity130 :: ('MESH:D014947', 'Disease') :: ['trauma']
@entity3264 :: (D018698,Chemical) :: ['glutamine']
